BloodLine

In our third episode, we speak to community members and advocates about their hopes for the future of FVIII inhibitor treatment as well as local and nationwide resources available to FVIII inhibitor patients.

In our second episode, we learn about the ten-year journey to bring HEMLIBRA® (emicizumab-kxwh) to market and take a deep look at the clinical trials of HEMLIBRA.

In our first episode, we meet patients from around the country who live with hemophilia A with factor VIII inhibitors and hear about their journeys first hand.